B. AMENDMENTS TO THE CLAIMS:

1. (Original) A method of creating a collection of isolated human tissue specimens, wherein each isolated human tissue specimen is preserved after a defined period of time following isolation of said specimen from its natural environment and is then stored, and wherein said defined period of time between isolation and preservation of various human tissue specimens is shorter than 25 minutes and shows a defined maximum deviation, which defined maximum deviation from said defined period of time is not more than 10%, based on said defined period of time.

2. (Original) A method as defined in claim 1,

characterized in that

the condition of said human tissue specimen following isolation thereof from its natural environment and prior to preservation thereof is recorded and documented.

3. (Amended) A method as defined in claim 1 ~~or claim 2~~,

characterized in that

said human tissue specimen has a defined volume.

4. (Amended) A method as defined in ~~any one of claims~~ claim 1 ~~through 3~~,

characterized in that

said defined maximum deviation from said defined period of time is not more than 5%, based on said defined period of time.

5. (Amended) A method as defined in ~~any one of claims~~ claim 1 ~~through 4~~,

characterized in that

said defined period of time is shorter than 15 minutes.

6. (Amended) A method as defined in ~~any one of claims 1 through~~ claim 5,

characterized in that

said defined period of time is 12 minutes.

7. (Amended) A method as defined in ~~any one of claims 1 through~~ claim 5,

characterized in that

said defined period of time is 10 minutes.

8. (Amended) A method as defined in ~~any one of claims~~ claim 1 ~~through 7~~,

characterized in that

preservation is effected by cryopreservation or by chemical preservation.

9. (Original) A method as defined in claim 8,

characterized in that

said chemical preservation involves the use of a cross-linking agent having reactive groups.

10. (Original) A method as defined in claim 9,

characterized in that

said cross-linking agent is selected from the group consisting of formaldehyde, polyaldehydes, ~~preferably dialdehydes,~~ polyepoxide compounds, ~~preferably diepoxide and/or triepoxide compounds,~~ and mixtures thereof.

11. (Amended) A method as defined in claim 1 ~~any of the previous claims~~,

characterized in that

said human tissue specimen is tumor-free tissue, tumor tissue and/or adipose tissue.

12. (Original) A method as defined in claim 11,

characterized in that

said tumor tissue is central or peripheral tumor tissue.

13. (Amended) A method as defined in ~~any one of claims~~ claim 1 ~~through 12~~,

characterized in that

data sets are assigned to said human tissue specimens.

14. (Original) A method as defined in claim 13,

characterized in that

said data sets contain information on the case history, medication, anesthesia, course of the operation, clinical parameters, and/or after-care data.

15. (Amended) A collection of human tissue specimens, containing isolated biological specimens which have been processed by the method defined in ~~any one of claims~~ claim 1 ~~through~~ ~~14~~.